Subscribe To
Bofa downgrades takeda on suspension narcolepsy drug trials
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to ...
October 6, 2021, 11:35 am
Bofa downgrades takeda on suspension narcolepsy drug trials
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to ...
October 6, 2021, 11:35 am
Bofa downgrades takeda on suspension narcolepsy drug trials
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to ...
October 6, 2021, 11:35 am
Hagens berman, national trial attorneys, alerts amplify energy corp. (ampy) investors to contact firm's attorneys now, firm investigating possible securities law violations
SAN FRANCISCO, Oct. 6, 2021 /PRNewswire/ -- Hagens Berman urges Amplify Energy Corp. (NYSE: AMPY) investors with significant losses to submit your lo...
October 6, 2021, 9:46 am
Hagens berman, national trial attorneys, alerts amplify energy corp. (ampy) investors to contact firm's attorneys now, firm investigating possible securities law violations
SAN FRANCISCO, Oct. 6, 2021 /PRNewswire/ -- Hagens Berman urges Amplify Energy Corp. (NYSE: AMPY) investors with significant losses to submit your lo...
October 6, 2021, 9:46 am
Hagens berman, national trial attorneys, alerts amplify energy corp. (ampy) investors to contact firm's attorneys now, firm investigating possible securities law violations
SAN FRANCISCO, Oct. 6, 2021 /PRNewswire/ -- Hagens Berman urges Amplify Energy Corp. (NYSE: AMPY) investors with significant losses to submit your lo...
October 6, 2021, 9:46 am
Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data
AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no s...
October 6, 2021, 8:41 am
Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data
AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no s...
October 6, 2021, 8:41 am
Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data
AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no s...
October 6, 2021, 8:41 am
Intellia to test second crispr therapeutic in hereditary angioedema patients
The New Zealand Medicines and Medical Devices safety Authority (MEDSAFE) has signed off Intellia Ther...
October 6, 2021, 8:29 am
Intellia to test second crispr therapeutic in hereditary angioedema patients
The New Zealand Medicines and Medical Devices safety Authority (MEDSAFE) has signed off Intellia Ther...
October 6, 2021, 8:29 am
Intellia to test second crispr therapeutic in hereditary angioedema patients
The New Zealand Medicines and Medical Devices safety Authority (MEDSAFE) has signed off Intellia Ther...
October 6, 2021, 8:29 am
Takeda provides update on tak-994 clinical program
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a
October 5, 2021, 7:33 pm
Takeda provides update on tak-994 clinical program
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a
October 5, 2021, 7:33 pm
Takeda provides update on tak-994 clinical program
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a
October 5, 2021, 7:33 pm
Takeda provides update on tak-994 clinical program
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a
October 5, 2021, 7:33 pm
Takeda provides update on tak-994 clinical program
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a
October 5, 2021, 7:33 pm
Mix telematics, ford pro intelligence bond to optimize road safety, efficiency
MiX Telematics Ltd (NYSE: MIXT) collaborated with Ford Motor Co's (NYSE: F) Ford Pro Intelligence to provide MiX North America customers operating...
October 5, 2021, 4:56 pm
Mix telematics, ford pro intelligence bond to optimize road safety, efficiency
MiX Telematics Ltd (NYSE: MIXT) collaborated with Ford Motor Co's (NYSE: F) Ford Pro Intelligence to provide MiX North America customers operating...
October 5, 2021, 4:56 pm
Mix telematics, ford pro intelligence bond to optimize road safety, efficiency
MiX Telematics Ltd (NYSE: MIXT) collaborated with Ford Motor Co's (NYSE: F) Ford Pro Intelligence to provide MiX North America customers operating...
October 5, 2021, 4:56 pm